Czechia· CZ-0255190

ZERCEPAC

A trastuzumab product containing trastuzumab, registered in Czechia by Accord Healthcare S.L.U., Barcelona. The same ATC class is registered in 14 of our 19 countries.

ATC L01FD01

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedZERCEPACATCL01FD01REGISTER NO.CZ-0255190PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Trastuzumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FD01 (trastuzumab), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Trastuzumab · ATC L01FD01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of trastuzumab costs, country by country.

Normalised to the WHO defined daily dose (28.6 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Trastuzumab · price per daily dose (28.6 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$116.57
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
TRASTUZUMAB
Manufacturer
Accord Healthcare S.L.U., Barcelona
Country
Czechia (CZ)
ATC code
L01FD01
ATC class
Trastuzumab
Defined daily dose
28.6 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

81 interactions on record for trastuzumab.

Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Trastuzumab · interactions on record

81 records

  • 34 severe
  • 47 moderate

Most severe, free to view

  • CladribineL01BB04severe
  • DoxorubicinL01DB01severe
  • DaunorubicinL01DB02severe
  • EpirubicinL01DB03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d194583a-6980-4541-a008-4fd8e2466e5f
GET /v1/drugs/d194583a-6980-4541-a008-4fd8e2466e5f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INF PLV CSL",
  "source": "sukl",
  "strength": "420MG",
  "pack_size": "1",
  "substance": "TRASTUZUMAB",
  "cz_kod_sukl": "0255190",
  "product_type": "BT",
  "substance_codes": "15536",
  "registration_state": "R",
  "registration_number": "EU/1/20/1456/003"
}

See everything about trastuzumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.